Literature DB >> 10337862

Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin.

F G Hamel1, G L Siford, J Fawcett, R E Chance, B H Frank, W C Duckworth.   

Abstract

Cellular metabolism studies were performed comparing human insulin with two rapid-acting analogs, LysB28ProB29 insulin (LysPro) and AspB10 insulin (B10-Asp). B10-Asp bound to isolated hepatocytes at 37 degrees C to a greater extent than LysPro or native insulin, which were equivalent. The rate of degradation was similar for the three materials, resulting in a significant reduction in the degraded/bound ratio for the B10 analog. The processing of membrane-bound material was examined by incubating cells with hormone at 4 degrees C, removing unbound insulin, and incubating the cells at 37 degrees C. Again, binding was greater for B10-Asp versus LysPro or native insulin, with a reduction in the degraded/bound ratio. Hormone internalization and processing was examined by an acid wash of cells incubated with 125I(A14)-labeled hormone to remove surface-bound materials. The processing rate was slower for B10-Asp versus LysPro or native insulin. Cell extraction and examination on molecular-sieve chromatography confirmed that B10-Asp was processed at a slower rate than either LysPro or native insulin. Intact B10-Asp was found in the cell after 4 hours, whereas all native insulin and LysPro were degraded by 90 to 120 minutes. B10-Asp also caused a greater incorporation of thymidine into DNA in cultured cells than LysPro or native insulin, which were similar. These data show that the cellular processing of LysPro is essentially identical to that of native insulin. However, B10-Asp has markedly different properties and is processed much more slowly. The prolonged cell residence time of B10-Asp could contribute to its greater effects on cell growth and mitogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10337862     DOI: 10.1016/s0026-0495(99)90059-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

Review 1.  Insulin X10 revisited: a super-mitogenic insulin analogue.

Authors:  B F Hansen; P Kurtzhals; A B Jensen; A Dejgaard; D Russell-Jones
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

2.  Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors.

Authors:  A M Hennige; V Strack; E Metzinger; G Seipke; H-U Häring; M Kellerer
Journal:  Diabetologia       Date:  2005-07-29       Impact factor: 10.122

3.  Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.

Authors:  Haim Werner; Ernst A Chantelau
Journal:  Diabetol Metab Syndr       Date:  2011-06-29       Impact factor: 3.320

4.  Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues.

Authors:  Tine Glendorf; Louise Knudsen; Carsten E Stidsen; Bo F Hansen; Anne Charlotte Hegelund; Anders R Sørensen; Erica Nishimura; Thomas Kjeldsen
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

5.  Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.

Authors:  Emily Jane Gallagher; Nyosha Alikhani; Aviva Tobin-Hess; Jeffrey Blank; Nicholas J Buffin; Zara Zelenko; Norbert Tennagels; Ulrich Werner; Derek LeRoith
Journal:  Diabetes       Date:  2013-07-08       Impact factor: 9.461

6.  Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin.

Authors:  Christine Bonnesen; Gitte-Mai Nelander; Bo Falck Hansen; Pia Jensen; Jonas S Krabbe; Marianne B Jensen; Anne Charlotte Hegelund; Jette E Svendsen; Martin B Oleksiewicz
Journal:  Cell Biol Toxicol       Date:  2009-11-08       Impact factor: 6.691

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.